# A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

> **NCT00849680** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 317 (actual)

## Conditions studied

- HIV-1
- HIV Infections

## Interventions

- **OTHER:** Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine
- **BIOLOGICAL:** Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
- **BIOLOGICAL:** Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
- **BIOLOGICAL:** Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
- **BIOLOGICAL:** Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
- **BIOLOGICAL:** Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
- **BIOLOGICAL:** Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
- **BIOLOGICAL:** Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
- **BIOLOGICAL:** Comparator: Placebo to MRKAd5 HIV-1 gag vaccine

## Key facts

- **NCT ID:** NCT00849680
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2005-03
- **Final completion:** 2010-02
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2015-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849680, "A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00849680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*